Compare SNSC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNSC | BMEA |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | New Zealand | United States |
| Employees | N/A | 37 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.2M | 42.4M |
| IPO Year | 2026 | 2021 |
| Metric | SNSC | BMEA |
|---|---|---|
| Price | $0.94 | $0.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.57 |
| AVG Volume (30 Days) | 30.7K | ★ 2.2M |
| Earning Date | 11-19-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $0.58 |
| 52 Week High | $3.15 | $2.24 |
| Indicator | SNSC | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 31.71 | 22.67 |
| Support Level | $0.82 | N/A |
| Resistance Level | $1.14 | $1.47 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 28.26 | 2.92 |
SunScout Holding Ltd is a clean-technology company engaged in the design, development, manufacturing, and commercialization of autonomous, solar-powered robotic mowers and related solar energy solutions. Its products are intended as alternatives to petrol-powered and grid-dependent electric lawn mowing equipment. The company's business comprises three lines of products and solutions, which are also its reportable segments: SunScout Products, Solar Power Development Solutions, and Engineering Products and Services. The majority of revenue is derived from the Solar Power Development Solutions segment, which develops and installs solar-energy systems for commercial, industrial, and institutional customers through EPC contracts. Geographically, maximum revenue is derived from New Zealand.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.